Preferences for Receiving Results from a Rare Disease Clinical Trial: A Survey of Subjects with Friedreich’s Ataxia and Their Parents

Ethics committees today recommend making the overall results of clinical trials available to the participants of therapeutic trials, and many guidelines have been developed for both general and specific situations. People with rare diseases are known to have expectations of the medical follow-up that may differ from people with non-rare diseases.